Skip to content
Screener

Precigen PGEN Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Gilead Sciences logo
Gilead SciencesGILD
$49.36B-11.4%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$395.96M-22.1%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$1.29B+81.1%
Regenxbio logo
RegenxbioRGNX
$386.62M-33.5%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$2.47B+358%
Enterprise value$2.56B+382%
P/S93.2×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Precigen’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356090-26-000017
(Amounts in thousands, except share data)March 31,2026December 31,2025
Commitments and contingencies (Note 14)
Shareholders' equity
Common stock, no par value, 700,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 355,903,977 shares and 353,910,926 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.
Additional paid-in capital2,369,5292,362,252
Accumulated deficit(2,349,277)(2,341,348)
Accumulated other comprehensive (loss) income(17)7
Total shareholders' equity20,23520,911
Total liabilities and shareholders' equity$138,627$155,505

Item 1. Condensed Consolidated Financial Statements

FAQ

What is Precigen's total liabilities & equity?
Precigen (PGEN) reported total liabilities & equity of $138.63M in Q1 2026.
How has Precigen's total liabilities & equity changed year-over-year?
Precigen's total liabilities & equity increased by 7.6% year-over-year, from $128.79M to $138.63M.
What is the long-term trend for Precigen's total liabilities & equity?
Over 5 years (2020 to 2025), Precigen's total liabilities & equity has grown at a -13.1% compound annual growth rate (CAGR), from $314.59M to $155.51M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Precigen's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude